- "The sell-off is not surprising to us and we continue to warn investors that the market for Testim will disappear in the foreseeable future," Summer Street says, regarding Auxilium Pharmaceuticals (AUXL) and Wednesday's news regarding an unfavorable district court ruling.
- Analyst Bart Classen also warns that when AndroGel goes generic in 2015, "almost no one will pay a premium for branded Testim."
- As for the December 6 PDUFA for Xiaflex, Classen is "skeptical that the FDA will approve [it] for Peyronies disease without an Ad Com."
Summer Street out with bearish commentary on Auxilium
Dec 5 2013, 09:29 ET